Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies

被引：5
作者：
Ascierto, Paolo A. [1 ]
机构：
[1] Fdn Pascale, Oncol Med Melanoma Immunoterapia Oncol & Terapia, Ist Nazl Tumori, IRCCS, Naples, Italy
来源：
TUMORI | 2013年 / 99卷 / 06期
关键词：
ipilimumab; immunotherapy; anti-CTLA-4; melanoma;
D O I：
10.1700/1390.15474
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the last 20 years, the survival and quality of life outcomes for patients with metastatic melanoma have been poor, with unsatisfactory results of chemotherapy and immunotherapy-based regimens. No drug or combination of drugs had any impact on survival until 2011, when ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), was approved for clinical use. Phase III trials have shown, for the first time ever, an overall survival benefit of ipilimumab compared with standard treatment, with a manageable toxicity profile. This review will discuss the mechanism of action of ipilimumab and the clinical trials that led to its approval.
引用
收藏
页码：E302 / E305
页数：4
相关论文
共 20 条
[1]   Use of ipilimumab in the treatment of melanoma [J].
Acharya, Utkarsh H. ;
Jeter, Joanne M. .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 :21-27
[2]   Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma [J].
Agarwala, Sanjiv S. .
MELANOMA RESEARCH, 2010, 20 (01) :1-10
[3]   Current systemic therapy for metastatic melanoma [J].
Agarwala, Sanjiv S. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) :587-595
[4]  
Di Giacomo AM, 2013, J CLIN ONCOL, V31
[5]   Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].
Downey, Stephanie G. ;
Klapper, Jacob A. ;
Smith, Franz O. ;
Yang, James C. ;
Sherry, Richard M. ;
Royal, Richard E. ;
Kammula, Udai S. ;
Hughes, Marybeth S. ;
Allen, Tamika E. ;
Levy, Catherine L. ;
Yellin, Michael ;
Nich, Geoffrey ;
White, Donald E. ;
Steinberg, Seth M. ;
Rosenberg, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688
[6]   A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma [J].
Hersh, Evan M. ;
O'Day, Steven J. ;
Powderly, John ;
Khan, Khuda D. ;
Pavlick, Anna C. ;
Cranmer, Lee D. ;
Samlowski, Wolfram E. ;
Nichol, Geoffrey M. ;
Yellin, Michael J. ;
Weber, Jeffrey S. .
INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) :489-498
[7]   Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].
Hodi, F. Stephen ;
O'Day, Steven J. ;
McDermott, David F. ;
Weber, Robert W. ;
Sosman, Jeffrey A. ;
Haanen, John B. ;
Gonzalez, Rene ;
Robert, Caroline ;
Schadendorf, Dirk ;
Hassel, Jessica C. ;
Akerley, Wallace ;
van den Eertwegh, Alfons J. M. ;
Lutzky, Jose ;
Lorigan, Paul ;
Vaubel, Julia M. ;
Linette, Gerald P. ;
Hogg, David ;
Ottensmeier, Christian H. ;
Lebbe, Celeste ;
Peschel, Christian ;
Quirt, Ian ;
Clark, Joseph I. ;
Wolchok, Jedd D. ;
Weber, Jeffrey S. ;
Tian, Jason ;
Yellin, Michael J. ;
Nichol, Geoffrey M. ;
Hoos, Axel ;
Urba, Walter J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723
[8]   Checkpoint blockade in cancer immunotherapy [J].
Korman, AJ ;
Peggs, KS ;
Allison, JP .
ADVANCES IN IMMUNOLOGY, VOL 90: CANCER IMMUNOTHERAPY, 2006, 90 :297-339
[9]   Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials [J].
Korn, Edward L. ;
Liu, Ping-Yu ;
Lee, Sandra J. ;
Chapman, Judith-Anne W. ;
Niedzwiecki, Donna ;
Suman, Vera J. ;
Moon, James ;
Sondak, Vernon K. ;
Atkins, Michael B. ;
Eisenhauer, Elizabeth A. ;
Parulekar, Wendy ;
Markovic, Svetomir N. ;
Saxman, Scott ;
Kirkwood, John M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :527-534
[10]   Enhancement of antitumor immunity by CTLA-4 blockade [J].
Leach, DR ;
Krummel, MF ;
Allison, JP .
SCIENCE, 1996, 271 (5256) :1734-1736
12